JP2019089849A5 - - Google Patents

Download PDF

Info

Publication number
JP2019089849A5
JP2019089849A5 JP2019043998A JP2019043998A JP2019089849A5 JP 2019089849 A5 JP2019089849 A5 JP 2019089849A5 JP 2019043998 A JP2019043998 A JP 2019043998A JP 2019043998 A JP2019043998 A JP 2019043998A JP 2019089849 A5 JP2019089849 A5 JP 2019089849A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
treating
compound
tautomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019043998A
Other languages
English (en)
Japanese (ja)
Other versions
JP6804580B2 (ja
JP2019089849A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019089849A publication Critical patent/JP2019089849A/ja
Publication of JP2019089849A5 publication Critical patent/JP2019089849A5/ja
Application granted granted Critical
Publication of JP6804580B2 publication Critical patent/JP6804580B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019043998A 2011-10-26 2019-03-11 ホルミルペプチド受容体様1(fprl−1)受容体モジュレーターとしてのn−尿素置換アミノ酸のアミド誘導体 Active JP6804580B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161551772P 2011-10-26 2011-10-26
US61/551,772 2011-10-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016150311A Division JP6496689B2 (ja) 2011-10-26 2016-07-29 ホルミルペプチド受容体様1(fprl−1)受容体モジュレーターとしてのn−尿素置換アミノ酸のアミド誘導体

Publications (3)

Publication Number Publication Date
JP2019089849A JP2019089849A (ja) 2019-06-13
JP2019089849A5 true JP2019089849A5 (cg-RX-API-DMAC7.html) 2019-11-14
JP6804580B2 JP6804580B2 (ja) 2020-12-23

Family

ID=47116500

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014538876A Active JP5982001B2 (ja) 2011-10-26 2012-10-23 ホルミルペプチド受容体様1(fprl−1)受容体モジュレーターとしてのn−尿素置換アミノ酸のアミド誘導体
JP2016150311A Active JP6496689B2 (ja) 2011-10-26 2016-07-29 ホルミルペプチド受容体様1(fprl−1)受容体モジュレーターとしてのn−尿素置換アミノ酸のアミド誘導体
JP2019043998A Active JP6804580B2 (ja) 2011-10-26 2019-03-11 ホルミルペプチド受容体様1(fprl−1)受容体モジュレーターとしてのn−尿素置換アミノ酸のアミド誘導体

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2014538876A Active JP5982001B2 (ja) 2011-10-26 2012-10-23 ホルミルペプチド受容体様1(fprl−1)受容体モジュレーターとしてのn−尿素置換アミノ酸のアミド誘導体
JP2016150311A Active JP6496689B2 (ja) 2011-10-26 2016-07-29 ホルミルペプチド受容体様1(fprl−1)受容体モジュレーターとしてのn−尿素置換アミノ酸のアミド誘導体

Country Status (32)

Country Link
US (9) US8658803B2 (cg-RX-API-DMAC7.html)
EP (2) EP2770989B1 (cg-RX-API-DMAC7.html)
JP (3) JP5982001B2 (cg-RX-API-DMAC7.html)
KR (1) KR102051687B1 (cg-RX-API-DMAC7.html)
CN (2) CN106518742B (cg-RX-API-DMAC7.html)
AR (2) AR088535A1 (cg-RX-API-DMAC7.html)
AU (3) AU2012329098B2 (cg-RX-API-DMAC7.html)
BR (2) BR122019025505B1 (cg-RX-API-DMAC7.html)
CA (1) CA2853648C (cg-RX-API-DMAC7.html)
CL (1) CL2014001080A1 (cg-RX-API-DMAC7.html)
CO (1) CO6960509A2 (cg-RX-API-DMAC7.html)
CY (1) CY1121604T1 (cg-RX-API-DMAC7.html)
DK (1) DK2770989T3 (cg-RX-API-DMAC7.html)
ES (2) ES2708997T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20181934T1 (cg-RX-API-DMAC7.html)
HU (1) HUE040145T2 (cg-RX-API-DMAC7.html)
IL (3) IL232204B (cg-RX-API-DMAC7.html)
IN (1) IN2014DN03424A (cg-RX-API-DMAC7.html)
LT (1) LT2770989T (cg-RX-API-DMAC7.html)
MX (2) MX376348B (cg-RX-API-DMAC7.html)
MY (1) MY172013A (cg-RX-API-DMAC7.html)
PH (2) PH12019500171B1 (cg-RX-API-DMAC7.html)
PL (1) PL2770989T3 (cg-RX-API-DMAC7.html)
PT (1) PT2770989T (cg-RX-API-DMAC7.html)
RS (1) RS58111B1 (cg-RX-API-DMAC7.html)
RU (2) RU2629205C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201903266YA (cg-RX-API-DMAC7.html)
SI (1) SI2770989T1 (cg-RX-API-DMAC7.html)
TW (1) TWI631099B (cg-RX-API-DMAC7.html)
UA (1) UA115043C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013062947A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201403222B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CN106518742B (zh) * 2011-10-26 2020-01-21 阿勒根公司 作为甲酰肽受体样-1(fprl-1)受体调节剂的n-脲取代的氨基酸的酰胺衍生物
US8541577B2 (en) * 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
ES2835825T3 (es) * 2013-03-06 2021-06-23 Allergan Inc Uso de agonistas del receptor 2 de péptidos formilados para tratar enfermedades inflamatorias oculares
KR20210024691A (ko) * 2013-03-06 2021-03-05 알러간, 인코포레이티드 피부 질환 치료용 포르밀 펩티드 수용체 2의 항진제의 용도
CA2917811C (en) * 2013-07-16 2021-08-31 Allergan, Inc. Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
TWI537251B (zh) 2013-10-09 2016-06-11 長庚大學 Fpr1拮抗劑的衍生物及其用途
CN105705484B (zh) * 2013-11-21 2018-09-14 阿勒根公司 作为甲酰肽受体调节剂的苯基氨基甲酸酯衍生物
TWI649305B (zh) 2013-11-28 2019-02-01 杏林製藥股份有限公司 脲衍生物、或其藥理學上所容許之鹽
US9663457B2 (en) 2014-04-09 2017-05-30 Allergan, Inc. Carbamoyl hydrazine derivatives as formyl peptide modulators
WO2015179707A1 (en) * 2014-05-21 2015-11-26 Allergan, Inc. Imidazole derivatives as formyl peptide receptor modulators
CN107848962B (zh) * 2015-05-27 2021-04-09 杏林制药株式会社 脲衍生物或其药理学上可接受的盐
AU2016266190A1 (en) 2015-05-27 2018-01-18 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
CA2992662A1 (en) * 2015-08-05 2017-02-09 Allergan, Inc. Phenyl urea analogs as formyl peptide repceptor 1 (fpr1) selective agonists
CN109715602A (zh) * 2016-03-28 2019-05-03 阿勒根公司 苯基脲衍生物作为n-甲酰肽受体调节剂
EP3442950A1 (en) 2016-04-12 2019-02-20 Allergan, Inc. Phenyl urea derivatives as n-formyl peptide receptor modulators
RU2768587C2 (ru) 2016-10-06 2022-03-24 Дайити Санкио Компани, Лимитед Производное мочевины
JP2020015664A (ja) * 2016-11-21 2020-01-30 宇部興産株式会社 含窒素多環式ヘテロ環誘導体
US10608869B2 (en) * 2017-03-20 2020-03-31 Nicira, Inc. Handling control-plane connectivity loss in virtualized computing environments
WO2019173182A1 (en) 2018-03-05 2019-09-12 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists
EP4234014A1 (en) * 2022-02-28 2023-08-30 Insusense ApS Amino acid based carbamates and/or ureas for the treatment of sortilin dependent diseases
WO2025144935A1 (en) * 2023-12-26 2025-07-03 Development Center For Biotechnology Heterocycle compounds as formyl peptide receptor modulators
WO2025233915A1 (en) 2024-05-10 2025-11-13 Allgenesis Biotherapeutics Inc. Use of an agonist of formyl peptide receptors 1 and 2 for treating ocular inflammatory diseases

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2533210A1 (fr) * 1982-09-17 1984-03-23 Lyon I Universite Claude Edulcorants de synthese
US4521210A (en) 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US5284828A (en) 1990-05-14 1994-02-08 Fujisawa Pharmaceutical Co. Ltd. Peptide compound and its preparation
JP3387948B2 (ja) 1992-12-04 2003-03-17 富山化学工業株式会社 新規なフェニルアラニン誘導体またはその塩
AU667995B2 (en) * 1993-02-15 1996-04-18 Bayer Aktiengesellschaft New pseudopeptides having an antiviral action
JP3597863B2 (ja) * 1993-11-05 2004-12-08 ワーナー−ランバート・コンパニー タンパク質:ファルネシルトランスフェラーゼの置換されたジ‐およびトリペプチド阻害剤
JPH11171896A (ja) * 1995-09-19 1999-06-29 Kirin Brewery Co Ltd 新規ペプチド化合物およびその医薬組成物
US6423689B1 (en) * 1997-12-22 2002-07-23 Warner-Lambert Company Peptidyl calcium channel blockers
US6548637B1 (en) * 1998-06-18 2003-04-15 Sepracor, Inc. Ligands for opioid receptors
US6243689B1 (en) 1998-12-29 2001-06-05 Robert G. Norton System and method for authorizing electronic funds transfer at a point of sale
AU6909300A (en) 1999-08-20 2001-03-19 Merck & Co., Inc. Substituted ureas as cell adhesion inhibitors
EP1162194A1 (en) 2000-06-06 2001-12-12 Aventis Pharma Deutschland GmbH Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
AU2002255485A1 (en) * 2001-01-19 2002-09-12 The Scripps Research Institute Hiv/fiv protease inhibitors
PT1453852E (pt) * 2001-12-12 2007-02-28 Wilex Ag Péptidos de arilguanidina selectivos como inibidores da urocinase
WO2004022529A2 (en) 2002-09-05 2004-03-18 Neurosearch A/S Diarylurea derivatives and their use as chloride channel blockers
AU2003259007A1 (en) * 2002-10-31 2004-05-25 Amersham Biosciences Ab Use of urea variants as affinity ligands
ATE447586T1 (de) 2002-11-07 2009-11-15 Takeda Pharmaceutical Fprl1-liganden und deren verwendung
KR100527361B1 (ko) * 2003-04-01 2005-11-09 주식회사 프로메디텍 데포르밀라제 저해제, 이의 제조방법, 및 이를 포함하는조성물
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
EP1692502A2 (en) * 2003-11-07 2006-08-23 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
CN1894580A (zh) * 2003-11-07 2007-01-10 阿卡蒂亚药品公司 脂氧素受体fprl1作为一种用于鉴定能有效治疗疼痛和炎症化合物的工具
EP1695961A4 (en) 2003-12-17 2007-10-24 Takeda Pharmaceutical UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
GB0417802D0 (en) * 2004-08-10 2004-09-15 Novartis Ag Organic compounds
CA2585210A1 (en) 2004-10-28 2006-05-11 Merck & Co., Inc. Pyrimidine and quinoline potentiators of metabotropic glutamate receptors
WO2006063113A2 (en) 2004-12-07 2006-06-15 Portola Pharmaceuticals, Inc. Ureas as factor xa inhibitors
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007076055A2 (en) 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
AU2007357448B2 (en) 2006-09-18 2012-09-06 Compugen Ltd Bioactive peptides and method of using same
AR065093A1 (es) 2007-02-05 2009-05-13 Merck Frosst Canada Ltd Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos
KR20090121832A (ko) 2008-05-23 2009-11-26 인제대학교 산학협력단 2-(2-히드록시벤조일)히드라진카르복시아미드 유도체 또는이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를유효 성분으로 함유하는 선택적 면역 억제용 약학적 조성물
US20100035932A1 (en) 2008-08-07 2010-02-11 Schepetkin Igor A Novel formyl peptide receptor like 1 agonists that induce macrophage tumor necrosis factor alpha and computational structure-activity relationship analysis of thereof
WO2010075416A1 (en) * 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
AU2011270872A1 (en) 2010-06-24 2013-01-31 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
WO2012074785A1 (en) 2010-12-03 2012-06-07 Allergan, Inc. Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
EP2673263A1 (en) 2011-02-11 2013-12-18 Allergan, Inc. Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators
US8653299B2 (en) 2011-03-17 2014-02-18 Allergan, Inc. Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
AU2012271562A1 (en) 2011-06-17 2014-01-30 Allergan, Inc. D -serine for the treatment of visual system disorders
GB2494851A (en) * 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
AU2012282977A1 (en) 2011-07-11 2014-02-06 Allergan, Inc. Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (FPRLl-1) receptor modulators
CN106518742B (zh) * 2011-10-26 2020-01-21 阿勒根公司 作为甲酰肽受体样-1(fprl-1)受体调节剂的n-脲取代的氨基酸的酰胺衍生物
US8541577B2 (en) 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
US8492556B2 (en) 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
EP2814815A1 (en) 2012-02-16 2014-12-24 Allergan, Inc. Imidazolidine-2,4-dione derivatives as n-formyl peptide receptor 2 modulators
ES2711363T3 (es) 2012-04-16 2019-05-03 Allergan Inc Derivados de (2-ureidoacetamido)alquilo como moduladores del receptor 2 de péptidos formilados
KR20210024691A (ko) * 2013-03-06 2021-03-05 알러간, 인코포레이티드 피부 질환 치료용 포르밀 펩티드 수용체 2의 항진제의 용도
ES2835825T3 (es) 2013-03-06 2021-06-23 Allergan Inc Uso de agonistas del receptor 2 de péptidos formilados para tratar enfermedades inflamatorias oculares
CA2917811C (en) 2013-07-16 2021-08-31 Allergan, Inc. Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators
US20150080466A1 (en) 2013-09-19 2015-03-19 Allergan, Inc. Diphenyl urea derivatives as formyl peptide receptor modulators
CN105684198B (zh) 2013-10-24 2018-08-03 丰田自动车株式会社 钠电池用正极活性物质和钠电池
CN105705484B (zh) 2013-11-21 2018-09-14 阿勒根公司 作为甲酰肽受体调节剂的苯基氨基甲酸酯衍生物
WO2015179707A1 (en) 2014-05-21 2015-11-26 Allergan, Inc. Imidazole derivatives as formyl peptide receptor modulators

Similar Documents

Publication Publication Date Title
JP2019089849A5 (cg-RX-API-DMAC7.html)
JP2019131569A5 (cg-RX-API-DMAC7.html)
JP2020037585A5 (cg-RX-API-DMAC7.html)
JP2015526458A5 (cg-RX-API-DMAC7.html)
JP2009533356A5 (cg-RX-API-DMAC7.html)
JP2015523546A5 (cg-RX-API-DMAC7.html)
JP2014506321A5 (cg-RX-API-DMAC7.html)
JP2012520249A5 (cg-RX-API-DMAC7.html)
WO2020263980A8 (en) IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE
JP2019505529A5 (cg-RX-API-DMAC7.html)
PH12021553232A1 (en) 2h-indazole derivatives and their use in the treatment of disease
JP2018537513A5 (cg-RX-API-DMAC7.html)
JP2013544786A5 (cg-RX-API-DMAC7.html)
JP2012521966A5 (cg-RX-API-DMAC7.html)
JPWO2020095971A5 (cg-RX-API-DMAC7.html)
JP2023011735A5 (cg-RX-API-DMAC7.html)
JP2022065024A5 (cg-RX-API-DMAC7.html)
Narabayashi Tremor mechanism
JP2019502719A5 (cg-RX-API-DMAC7.html)
AR092842A1 (es) Tratamiento de enfermedades inflamatorias oculares usando laquinimod
JP2021503451A5 (cg-RX-API-DMAC7.html)
JP2019507786A5 (cg-RX-API-DMAC7.html)
RU2016105310A (ru) Пиперазин-замещенные мостиковые производные спиро[2.4]гептана в качестве агонистов alx рецептора
JP2020510061A5 (cg-RX-API-DMAC7.html)
PH12020550722A1 (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye